• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

    113.22 -0.68 (-0.60%)
    Streaming Delayed Price Updated: 12:39 PM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 523,427
    Open 113.34
    Bid (Size) 113.20 (200)
    Ask (Size) 113.31 (100)
    Prev. Close 113.90
    Today's Range 112.10 - 113.78
    52wk Range 61.23 - 116.84
    Shares Outstanding 142,334,900
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
    As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge... 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    1 Cash-Producing Stock to Target This Week and 2 We Question
    Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
    Via StockStory

    Performance

    YTD
    +61.0%
    +61.0%
    1 Month
    +7.5%
    +7.5%
    3 Month
    +46.7%
    +46.7%
    6 Month
    +82.2%
    +82.2%
    1 Year
    +54.5%
    +54.5%

    More News

    Read More
    Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup ↗
    Via Chartmill
    News headline image
    Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗
    Via The Motley Fool
    News headline image
    1 Mid-Cap Stock on Our Watchlist and 2 We Avoid
    Via StockStory
    Topics Fraud
    Halozyme Therapeutics (NASDAQ:HALO) Meets Minervini’s High-Growth Trend Template ↗
    Via Chartmill
    Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metrics ↗
    Via Chartmill
    News headline image
    3 Market-Beating Stocks for Long-Term Investors
    Via StockStory
    News headline image
    1 Healthcare Stock with Exciting Potential and 2 We Avoid
    Via StockStory
    Topics Economy
    News headline image
    2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
    Via StockStory
    News headline image
    Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗
    Via Chartmill
    News headline image
    The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call
    Via StockStory
    Topics Earnings Intellectual Property
    News headline image
    HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance
    Via StockStory
    News headline image
    Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    1 Profitable Stock to Research Further and 2 We Ignore
    Via StockStory
    News headline image
    Halozyme Therapeutics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales
    Via StockStory
    News headline image
    What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
    Via StockStory
    News headline image
    3 Growth Stocks Set to Flourish
    Via StockStory
    News headline image
    1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
    Via StockStory
    Topics Energy
    News headline image
    1 Value Stock Worth Investigating and 2 Facing Headwinds
    Via StockStory
    News headline image
    2 Reasons to Like HALO and 1 to Stay Skeptical
    Via StockStory
    Topics Stocks
    News headline image
    1 Surging Stock for Long-Term Investors and 2 We Brush Off
    Via StockStory
    News headline image
    2 Profitable Stocks Worth Your Attention and 1 We Question
    Via StockStory
    Topics Credit Cards

    Frequently Asked Questions

    Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
    Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
    The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
    What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
    The current price of Halozyme Therapeutics, Inc. - Common Stock is 113.22
    When was Halozyme Therapeutics, Inc. - Common Stock last traded?
    The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 09/28/26 12:39 PM ET
    What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
    The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 16.12B
    How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
    Halozyme Therapeutics, Inc. - Common Stock has 16B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.